These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37900721)

  • 41. Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective.
    Richy F; Ethgen O; Bruyere O; Mawet A; Reginster JY
    J Bone Miner Res; 2004 Dec; 19(12):1955-60. PubMed ID: 15537437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of 3D finite element models from simulated DXA images for biofidelic simulations of sideways fall impact to the hip.
    Grassi L; Fleps I; Sahlstedt H; Väänänen SP; Ferguson SJ; Isaksson H; Helgason B
    Bone; 2021 Jan; 142():115678. PubMed ID: 33022451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of opportunistic QCT-based osteoporosis screening for the prediction of incident vertebral fractures.
    Rühling S; Schwarting J; Froelich MF; Löffler MT; Bodden J; Hernandez Petzsche MR; Baum T; Wostrack M; Aftahy AK; Seifert-Klauss V; Sollmann N; Zimmer C; Kirschke JS; Tollens F
    Front Endocrinol (Lausanne); 2023; 14():1222041. PubMed ID: 37576975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CT.
    Pisu M; Kopperdahl DL; Lewis CE; Saag KG; Keaveny TM
    J Bone Miner Res; 2019 Jul; 34(7):1229-1239. PubMed ID: 30779860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk.
    Luo C; Qin SX; Wang QY; Li YF; Qu XL; Yue C; Hu L; Sheng ZF; Wang XB; Wan XM
    J Endocrinol Invest; 2023 Feb; 46(2):367-379. PubMed ID: 36044169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [No Abstract]   [Full Text] [Related]  

  • 50. Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA.
    Ito K
    BMJ Open; 2018 Sep; 8(9):e022585. PubMed ID: 30181186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
    Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK
    Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.
    Söreskog E; Lindberg I; Kanis JA; Åkesson KE; Willems D; Lorentzon M; Ström O; Berling P; Borgström F
    Osteoporos Int; 2021 Mar; 32(3):585-594. PubMed ID: 33409591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
    Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
    PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China.
    You R; Liu J; Ke L; Wan M; Zhang Y; Yu G; Mori T
    Front Pharmacol; 2022; 13():816248. PubMed ID: 35370751
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.
    Schousboe JT; Ensrud KE; Nyman JA; Kane RL; Melton LJ
    J Clin Densitom; 2006; 9(2):133-43. PubMed ID: 16785071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis.
    Marín F; López-Bastida J; Díez-Pérez A; Sacristán JA;
    Calcif Tissue Int; 2004 Mar; 74(3):277-83. PubMed ID: 14708042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 3i hip fracture liaison service with nurse and physician co-management is cost-effective when implemented as a standard clinical program.
    Beaupre LA; Lier D; Smith C; Evens L; Hanson HM; Juby AG; Kivi P; Majumdar SR;
    Arch Osteoporos; 2020 Jul; 15(1):113. PubMed ID: 32699946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness of alendronate in the management of osteoporosis.
    Kanis JA; Adams J; Borgström F; Cooper C; Jönsson B; Preedy D; Selby P; Compston J
    Bone; 2008 Jan; 42(1):4-15. PubMed ID: 18156107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.